Want to see IN:NURECA full AI Analyst Report?
Top Page
Nureca Ltd.
(NURECA)
Select Model
Select Model
Rating:61Neutral
Price Target:
₹319.00
▲(6.74% Upside)
Action:Reiterated
Date:09/29/26
The score is driven by a mixed financial profile: a very strong, low-leverage balance sheet and improving revenue/profitability are positives, but thin margins and uneven cash-flow conversion keep quality moderate. Technicals are supportive with a clear uptrend and positive momentum, while a very high P/E and lack of dividend yield data weigh heavily on valuation.
Positive Factors
Very Low Leverage
The conservatively financed balance sheet reduces financial risk and gives Nureca flexibility to fund operations, product development, and distribution growth without relying heavily on borrowing. Low leverage is especially valuable while earnings remain volatile and helps preserve resilience through weaker periods.
Negative Factors
Thin Profit Margins
Very thin margins leave limited protection against discounting, logistics costs, returns, or changes in product mix. Even with revenue growth, small shifts in operating expenses or selling prices could materially affect earnings, making durable profit expansion dependent on improved scale and cost discipline.
Read all positive and negative factors
Positive Factors
Negative Factors
Very Low Leverage
The conservatively financed balance sheet reduces financial risk and gives Nureca flexibility to fund operations, product development, and distribution growth without relying heavily on borrowing. Low leverage is especially valuable while earnings remain volatile and helps preserve resilience through weaker periods.
Read all positive factors
Nureca Ltd. (NURECA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹2.89B
Dividend Yield0.38%
Average Volume (3M)857.00
Price to Earnings (P/E)63.4
Beta (1Y)1.03
Revenue Growth33.66%
EPS Growth17.10%
CountryIN
Employees154
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)4.74
Shares Outstanding9,541,920
10 Day Avg. Volume767
30 Day Avg. Volume857
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)1.13
Price to Sales (P/S)1.39
P/FCF Ratio116.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nureca Ltd. Business Overview & Revenue Model
Company Description
Operating in India, Nureca Limited is a business-to-consumer (B2C) firm specializing in home healthcare and general wellness solutions. Their extensive product portfolio addresses various health needs, encompassing items for managing chronic condi...
How the Company Makes Money
Nureca makes money primarily by selling home healthcare and wellness products under its owned brands (notably Dr Trust and Dr Physio). Revenue is generated from (1) direct product sales to end consumers through the company’s own online storefronts...
Nureca Ltd. Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
84
Very Positive
Cash Flow
45
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.74B | 1.47B | 1.10B | 919.28M | 1.11B | 2.56B |
| Gross Profit | 444.82M | 352.34M | 231.33M | 311.42M | 355.94M | 1.23B |
| EBITDA | 111.18M | 85.19M | 48.95M | 2.41M | -79.04M | 632.04M |
| Net Income | 47.60M | 20.82M | 8.46M | -17.94M | -82.50M | 449.60M |
Balance Sheet | ||||||
| Total Assets | 2.31B | 1.96B | 2.10B | 2.05B | 2.07B | 2.19B |
| Cash, Cash Equivalents and Short-Term Investments | 735.52M | 424.31M | 736.29M | 1.44B | 1.02B | 927.10M |
| Total Debt | 66.01M | 22.59M | 49.66M | 25.16M | 33.27M | 44.05M |
| Total Liabilities | 433.97M | 153.96M | 156.91M | 120.54M | 116.97M | 159.32M |
| Stockholders Equity | 1.88B | 1.81B | 1.94B | 1.93B | 1.95B | 2.03B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 17.45M | -234.06M | -37.98M | 98.31M | -46.00M |
| Operating Cash Flow | 0.00 | 85.74M | -190.83M | -27.12M | 102.27M | 13.99M |
| Investing Cash Flow | 0.00 | 81.20M | 84.39M | 175.76M | -164.56M | -30.89M |
| Financing Cash Flow | 0.00 | -184.66M | -1.69M | -13.03M | -15.07M | -73.02M |
Nureca Ltd. Technical Analysis
Neutral
298.85
Price Trends
330.33
Negative
301.66
Positive
286.18
Positive
Market Momentum
-6.33
Positive
34.60
Neutral
17.20
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NURECA, the sentiment is Neutral. The current price of 298.85 is below the 20-day moving average (MA) of 330.91, below the 50-day MA of 330.33, and above the 200-day MA of 286.18, indicating a neutral trend. The MACD of -6.33 indicates Positive momentum. The RSI at 34.60 is Neutral, neither overbought nor oversold. The STOCH value of 17.20 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:NURECA.
Nureca Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | ₹14.36B | 26.41 | ― | 1.00% | 10.68% | -1.04% | |
68 Neutral | ₹89.57B | 25.11 | ― | 3.92% | 13.04% | 4.60% | |
63 Neutral | ₹98.04B | 38.22 | ― | 0.23% | -27.51% | -34.49% | |
61 Neutral | ₹2.89B | 63.40 | ― | 0.38% | 33.66% | 17.10% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹38.56B | -40.55 | ― | 0.08% | 78.89% | -50.10% |
* General Sector Average
IN:NURECA
Nureca Ltd.
302.65
40.85
15.60%
IN:AMRUTANJAN
Amrutanjan Health Care Limited
491.10
-245.72
-33.35%
IN:BLUEJET
Blue Jet Healthcare Limited
517.95
-132.49
-20.37%
IN:PGHL
Procter & Gamble Health Ltd.
5,396.05
-553.78
-9.31%
IN:SANOFICONR
Sanofi Consumer Healthcare India Limited
3,325.65
-1,282.03
-27.82%
IN:ZOTA
Zota Health Care Ltd.
1,271.10
-283.14
-18.22%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.